31 results
DEFM14A
SQZB
SQZ Biotechnologies Co
23 Jan 24
Proxy related to merger
4:31pm
related AEs and no evaluable patient met pre-specified DLT criteria.
Safety Data & Tolerability Assessment Summary
Cohort 1
(n=4)
Cohort 2
(n=1)
Total … with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. The duration of patents outside
PREM14A
SQZB
SQZ Biotechnologies Co
12 Jan 24
Preliminary proxy related to merger
8:57am
doses, mostly low-grade related AEs and no evaluable patient met pre-specified DLT criteria.
Safety Data & Tolerability Assessment Summary
Cohort 1
(n … , including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions
8-K
EX-2.1
SQZB
SQZ Biotechnologies Co
22 Dec 23
Entry into a Material Definitive Agreement
5:18pm
agreement (including an advance Tax ruling and/or an advance pricing agreement), settle any claim or assessment in respect of Taxes, request a ruling … Course of Business, or consent to any extension or waiver of the limitation period applicable to any claim or assessment in respect of Taxes, in each case
PRE 14A
ambh3ink
10 Apr 23
Preliminary proxy
4:31pm
8-K
kitdm8z33
9 Dec 21
Other Events
7:30am
8-K
EX-99.1
ag8c3q
9 Dec 21
Other Events
7:30am
8-K
EX-99.2
sd0g2o7k33jicrq
9 Dec 21
Other Events
7:30am
8-K
EX-99.3
0qzpp19116up
9 Dec 21
Other Events
7:30am
S-3
EX-1.2
94r4z0f49 dtc
12 Nov 21
Shelf registration
12:00am
DEF 14A
r70u6l9ih 9j
26 Apr 21
Definitive proxy
5:00pm
10-K
60ycns
18 Mar 21
Annual report
6:31am
424B4
98w86cduz4ostdz 6u0b
12 Feb 21
Prospectus supplement with pricing info
5:10pm